Facebook-f X-twitter Linkedin-in Instagram
  • Client News

CURE Pharmaceutical expands DEA license to manufacture cannabinoid molecules

CURE Pharmaceutical announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD).
Read Full Story
  • Client News

CURE Pharmaceutical and CUREfilm featured on Drug Development & Delivery

The actual design and construction of an oral film capable of effective therapeutic delivery can be challenging and requires the…
Read Full Story
  • Client News

CUREfilm redefines how medicines are delivered and experienced

The CUREfilm technology, developed by Cure Pharmaceutical, delivers drugs through a dissolvable strip that can be applied in the oral…
Read Full Story

Contact Us

SEE HOW WE CAN ACCELERATE YOUR BUSINESS TODAY!